Pegfilgrastim
- Generic Name
- Pegfilgrastim
- Brand Names
- Fulphila, Fylnetra, Neulasta, Udenyca, Ziextenzo, Cegfila (previously Pegfilgrastim Mundipharma), Nyvepria, Pelgraz, Grasustek, Pelmeg, Stimufend
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 208265-92-3
- Unique Ingredient Identifier
- 3A58010674
- Background
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, filgrastim. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of de...
- Indication
Pegfilgrastim is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
...
- Associated Conditions
- Chemotherapy Induced Neutropenia, Hematopoietic Subsyndrome of Acute Radiation Syndrome, Infection
- Associated Therapies
- -
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-08-21
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT03639948
- Locations
- 🇺🇸
The University of Kansas Cancer Center, Overland Park Clinic, Overland Park, Kansas, United States
🇺🇸Texas Oncology- Baylor, Dallas, Texas, United States
🇺🇸The University of Kansas Cancer Center, Westwood Campus, Kansas City, Kansas, United States
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations
- Conditions
- Interventions
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 271
- Registration Number
- NCT03609216
- Locations
- 🇺🇸
Mary Bird Perkins Cancer Center - Metairie, Metairie, Louisiana, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Henry Ford Saint John Hospital - Academic, Grosse Pointe Woods, Michigan, United States
Safety and Efficacy of Pegteograstim in Korean Breast Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2018-07-02
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 63
- Registration Number
- NCT03575520
- Locations
- 🇰🇷
Division of Medical Oncology, Severance Breast Cancer Clinic, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Centre Leon Berard
- Target Recruit Count
- 90
- Registration Number
- NCT03571633
- Locations
- 🇫🇷
Centre Hospitalier Universitaire de Saint Etienne, Saint-Étienne, France
🇫🇷Centre Leon Berard, Lyon, France
🇫🇷CHRU Besançon, Besançon, France
Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.
- First Posted Date
- 2018-01-19
- Last Posted Date
- 2018-01-19
- Lead Sponsor
- Gema Biotech S.A.
- Target Recruit Count
- 120
- Registration Number
- NCT03404752
- Locations
- 🇦🇷
COIBA, Buenos Aires, Bs As, Argentina
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2017-12-19
- Target Recruit Count
- 24
- Registration Number
- NCT03376503
- Locations
- 🇻🇳
Vietnam National Cancer Institute (Hospital K), Hanoi, Vietnam
Neoadjuvant Dose-Dense For Early Her2Neu Positive Breast Cancer
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 7
- Registration Number
- NCT03329378
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇺🇸Mount Sinai Beth Israel, New York, New York, United States
🇺🇸Mount Sinai West, New York, New York, United States
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- University of Wisconsin, Madison
- Target Recruit Count
- 29
- Registration Number
- NCT03301350
- Locations
- 🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸Columbia St. Mary's Cancer Center, Milwaukee, Wisconsin, United States
🇺🇸Aspirus Regional Cancer Center Wausau, Wausau, Wisconsin, United States
Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia
- Conditions
- Interventions
- First Posted Date
- 2017-09-27
- Last Posted Date
- 2021-01-15
- Lead Sponsor
- BeyondSpring Pharmaceuticals Inc.
- Target Recruit Count
- 221
- Registration Number
- NCT03294577
- Locations
- 🇺🇦
Dnipropetrovsk City Multifunctional Hospital #4 Oncology Department, Dnepropetrovsk, Ukraine
🇺🇦Prykarpatskiy Regional Oncological Center, Ivano-Frankivs'k, Ukraine
🇺🇦V.T. Zaycev Institute, Kharkiv, Ukraine
Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 54
- Registration Number
- NCT03220022
- Locations
- 🇺🇸
University of Illinois College of Medicine - Chicago, Chicago, Illinois, United States
🇺🇸Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸Boston Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.